Walleye Capital
ATRA icon

Walleye Capital’s Atara Biotherapeutics ATRA Stock Holding History

Walleye Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,169
Closed -$220K – 4377
2025
Q4 		$220K Buy
+12,169
New +$182K ﹤0.01% 3493
2023
Q2 		– Sell
-3,536
Closed -$256K – 4297
2023
Q1 		$256K Sell
3,536
-4,116
-54% -$399K ﹤0.01% 2252
2022
Q4 		$627K Sell
7,652
-7,388
-49% -$770K 0.01% 1310
2022
Q3 		$1.42M Buy
+15,040
New +$1.69M 0.03% 739
2022
Q2 		– Sell
-1,274
Closed -$296K – 2349
2022
Q1 		$296K Buy
+1,274
New +$406K 0.01% 1316
2020
Q1 		– Sell
-408
Closed -$168K – 930
2019
Q4 		$168K Buy
+408
New +$141K 0.01% 1191

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Walleye Capital's ATRA Position: Q1 2026 in Review

Walleye Capital sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 12,169 shares — an estimated $220K sold.

Walleye Capital first reported a position in ATRA in Q4 2019 and held it in 6 quarters. The position peaked at $1.42M in Q3 2022. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Walleye Capital reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 12,169 Atara Biotherapeutics shares in Q1 2026, an estimated $220K.
  • Walleye Capital first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 6 quarters.
  • Walleye Capital's Atara Biotherapeutics position peaked at $1.42M in Q3 2022.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.